Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 795-803

  Masago, Katsatsuhiro ^a   Fujita, Shiro ^b   Togashi, Yosuke ^a   Kim, Young Hak ^a   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Nagai, Hiroki ^a   Irisa, Kaoru ^a   Sakamori, Yuichi ^a   Mio, Tadashi ^b   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Epidermal growth factor receptor somatic mutation; Gefitinib; Insulin like growth factor 1; Insulin like growth factor binding protein 3; Non small cell lung cancer

Indexed keywords

GEFITINIB; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; IMMUNORADIOMETRIC ASSAY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID ANALYSIS; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK FACTOR; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79960754680     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1354     Document Type: Article

References (49)

1. Chou TY, Chiu CH, Li LH, et al: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757, 2005.
2. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203, 2004.
3. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005. (Pubitemid 40425952)
4. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005. (Pubitemid 40175767)
5. Ramalingam SS, Dahlberg SE, Langer CJ, et al: Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26: 60-65, 2008.
6. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003. (Pubitemid 46621858)
7. Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23: 8081-8092, 2005. (Pubitemid 46657411)
8. Cappuzzo F, Finocchiaro G, Metro G, et al: Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 58: 31-45, 2006.
9. Cortes-Funes H, Gomez C, Rosell R, et al: Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small cell lung cancer patients. Ann Oncol 16: 1081-1086, 2005. (Pubitemid 41418309)
10. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.
11. Hirsch FR, Varella-Garcia M, McCoy J, et al: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23: 6838-6845, 2005.
12. Kim KS, Jeong JY, Kim YC, et al: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11: 2244-2251, 2005.
13. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
14. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
15. Rosell R, Ichinose Y, Taron M, et al: Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50: 25-33, 2005. (Pubitemid 41297466)
16. Sonobe M, Manabe T, Wada H and Tanaka F: Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 93: 355-363, 2005. (Pubitemid 43080038)
17. Takano T, Ohe Y, Sakamoto H, et al: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 23: 6829-6837, 2005.
18. Tomizawa Y, Iijima H, Sunaga N, et al: Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11: 6816-6822, 2005. (Pubitemid 41428736)
19. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489, 2000.
20. Furstenberger G and Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 3: 298-302, 2002. (Pubitemid 34546447)
21. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998. (Pubitemid 28209997)
22. Bruning PF, Van Doorn J, Bonfrer JM, et al: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62: 266-270, 1995.
23. Peyrat JP, Bonneterre J, Hecquet B, et al: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29: 492-497, 1993. (Pubitemid 23036292)
24. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998. (Pubitemid 28067285)
25. Chan JM, Stampfer MJ, Ma J, et al: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94: 1099-1106, 2002. (Pubitemid 34830730)
26. Wolk A, Mantzoros CS, Andersson SO, et al: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911-915, 1998. (Pubitemid 28304159)
27. Wei EK, Ma J, Pollak MN, et al: C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 15: 750-755, 2006.
28. Wei EK, Ma J, Pollak MN, et al: A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14: 850-855, 2005. (Pubitemid 40478547)
29. Ma J, Pollak MN, Giovannucci E, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620-625, 1999. (Pubitemid 29194048)
30. Lukanova A, Lundin E, Toniolo P, et al: Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 101: 549-554, 2002.
31. Lukanova A, Lundin E, Micheli A, et al: Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control 14: 285-292, 2003. (Pubitemid 36649151)
32. Wolpin BM, Michaud DS, Giovannucci EL, et al: Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer 97: 98-104, 2007. (Pubitemid 47012086)
33. Wolpin BM, Michaud DS, Giovannucci EL, et al: Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 67: 7923-7928, 2007. (Pubitemid 47281389)
34. Michaud DS, Wolpin B, Giovannucci E, et al: Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16: 2101-2109, 2007. (Pubitemid 47621187)
35. Schumacher FR, Cheng I, Freedman ML, et al: A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 19: 3089-3101, 2010.
36. Carboni JM, Wittman M, Yang Z, et al: BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8: 3341-3349, 2009.
37. Clemens PL, Park JS and Cohen MB: BMS-754807, an oral dual IGF-IR/IR inhibitor: first-in-human single-dose study of safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Proceedings of the AACR-NCI-EORTC International Conference November 15-19, Boston, MA. Mol Cancer Ther 8 (Suppl. 1): A101, 2009.
38. Desai J, Solomon B and Davis ID: Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. J Clin Oncol 28: 15s, 2010.
39. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005. (Pubitemid 41161259)
40. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004. (Pubitemid 39665498)
41. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002. (Pubitemid 34074005)
42. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al: Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68: 8322-8332, 2008.
43. Huang F, Greer A, Hurlburt W, et al: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69: 161-170, 2009.
44. Werner H and Le Roith D: New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Mol Life Sci 57: 932-942, 2000. (Pubitemid 30461834)
45. Yu H, Spitz MR, Mistry J, Gu J, Hong WK and Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156, 1999. (Pubitemid 29042692)
46. Lukanova A, Toniolo P, Akhmedkhanov A, et al: A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 92: 888-892, 2001. (Pubitemid 32467380)
47. Lin Y, Tamakoshi A, Kikuchi S, et al: Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 110: 584-588, 2004. (Pubitemid 38658024)
48. Baxter RC: Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 54: 145-148, 2001.
49. Haq M, Shaeii AE, Zervos EE and Rosemurgy AS: In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs. Int J Surg Investig 1: 459-465, 2000.